Rexahn options RX3117 rights to Teva; deal terminated
Rexahn Pharmaceuticals (oncology, CNS, and sexual dysfunction treatments) has granted Teva Pharmaceutical Industries, through its Teva Innovative Ventures partnering division, an exclusive option to license rights to develop and sell its RX3117 cancer candidate.
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com